Abstract Body

Background: Genotypic tools for HIV-2 tropism determination have been recently established. In vitro studies have demonstrated that maraviroc has efficacy against HIV-2. Currently, maraviroc use is only considered in highly pre-treated HIV-2 patients. However, R5/X4 tropism distribution is still unknown during HIV-2 infection. The aim of this study was to describe HIV-2 tropism distribution in treatment-experienced patients and to compare CD4 cell count and number of drug resistances mutations in R5 and X4 viruses. Methodology: All samples received for HIV-2 tropism in routine testing between April 2009 and June 2013 issued from ART treated patients experiencing virological failure were included. At time of tropism determination, CD4 cell count, HIV-2 viral load and genotypic resistance testing (protease, RT, integrase) results were collected. Genotypic resistance tests were interpreted according to the new European resistance algorithm (http://www.geno2pheno.org/). Associations between tropism and variables were tested by Mann-Whitney or Fisher exact tests. Results: 83 patients were included (47 Group A, 33 Group B, 3 not available). Among them, CD4 cell counts, HIV-2 viral load, and genotypic resistance results were available in 67 samples (81%), 75 (90%) and 77 (93%), respectively. 35 (42%) viruses were predicted as R5 and 48 (58%) as X4; with no significant difference between groups A and B (p = 0.65). Median CD4 cells counts were 220 (IQR = 155-395) and 88 cells/mm3 (IQR = 52-171) in R5 and X4 groups, respectively (p<0.0001). Tropism distribution among CD4 cell counts strata is depicted in the table below. Among R5 and X4 groups, median HIV-2 viral load was 1,417 (IQR = 417-11,910) and 2,187 copies/mL (IQR = 526-4,730), respectively (p = 0.38). Patients with X4 viruses exhibited a significant higher number of drug resistance mutations in protease, RT, and integrase regions than patients with R5 viruses (median = 3 [IQR = 1-5] versus 1 [IQR = 0-4]; p = 0.01). Conclusions: A high proportion of X4 viruses was observed (58%), particularly in patients with CD4 cell count below 100/mm3. Patients with X4 viruses had lower CD4 cell counts and a higher number of drug resistance mutations, suggesting a longer treatment history. Thus, as in HIV-1, maraviroc use in HIV-2 salvage therapy may be compromised by a high proportion of X4 viruses. These results suggest that maraviroc use must be evaluated earlier in the infection in order to optimize the HIV-2 limited therapeutic arsenal.